Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
740 stopped studies mapped to Myeloproliferative Neoplasm and descendants · 88% state a reason
Over the 740 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04914676 | Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With… | Phase 2 | terminated | Jun 4, 2021 | University of Florida | PI decision to close study early due to limited data due to accrual goal not being met | Enrollment / accrual |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of… | Phase 1 / Phase 2 | terminated | Jul 23, 2019 | Hoffmann-La Roche | Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed… | Efficacy / futility |
| NCT03755518 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary…(FREEDOM) | Phase 3 | terminated | Nov 28, 2018 | Celgene | Slow accrual. | Enrollment / accrual |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | Phase 1 | terminated | Mar 17, 2020 | Celularity Incorporated | Business reasons | Sponsor / business decision |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory… | Phase 1 | terminated | Aug 26, 2020 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | Phase 1 | terminated | Feb 25, 2020 | Taiho Oncology, Inc. | The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible… | Enrollment / accrual |
| NCT04582864 | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)… | Phase 2 | terminated | Oct 12, 2020 | Washington University School of Medicine | The sponsor is no longer supporting the drug | Other (stated, no rule matched) |
| NCT03939585 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells… | Phase 1 | withdrawn | May 7, 2019 | Leland Metheny | Lack of funding | Funding |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia… | Phase 1 | terminated | Feb 16, 2021 | ALX Oncology Inc. | While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2. | Other (stated, no rule matched) |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | Phase 1 | withdrawn | Mar 22, 2021 | Duke University | Study halted prematurely, prior to enrollment of first participant. | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory… | Phase 1 | withdrawn | Mar 4, 2022 | Beijing Boren Hospital | Difficulty in joining the group | Other (stated, no rule matched) |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in… | Phase 2 | terminated | Feb 21, 2021 | Ensoma | This study was voluntarily terminated due to a business decision not to proceed and not due to any… | Safety / toxicity |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | Phase 1 | terminated | Nov 1, 2022 | Institute of Hematology & Blood Diseases Hospital, China | It did not reach the expected results of clinical trial | Other (stated, no rule matched) |
| NCT02610062 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of… | Phase 1 | terminated | Nov 20, 2015 | Astellas Pharma Global Development, Inc. | Business decision by sponsor | Sponsor / business decision |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT02864290 | A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in… | Phase 1 | terminated | Aug 12, 2016 | Astellas Pharma Global Development, Inc. | Study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT02270463 | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in… | Phase 1 / Phase 2 | terminated | Oct 21, 2014 | Stemline Therapeutics, Inc. | not stated | Not stated |
| NCT03541369 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With…(20170528) | Phase 1 | terminated | May 30, 2018 | Amgen | Premature discontinuation of study, a strategic decision. | Sponsor / business decision |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | Phase 1 / Phase 2 | withdrawn | Jul 29, 2021 | Guenther Koehne | Could not accrue | Enrollment / accrual |
| NCT03735875 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 8, 2018 | M.D. Anderson Cancer Center | This study was terminated early due to other competing trials, therefore did not go on to the Phase… | Other (stated, no rule matched) |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
| NCT05682170 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | terminated | Jan 12, 2023 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with… | Phase 1 | withdrawn | Apr 21, 2023 | City of Hope Medical Center | Withdrawn -ctms | Other (stated, no rule matched) |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid… | Phase 2 | withdrawn | May 11, 2023 | Wake Forest University Health Sciences | PI decided not to move forward with the study | Other (stated, no rule matched) |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Institute of Hematology & Blood Diseases Hospital, China | withdrawn | Other (stated, no rule matched) |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance… | Phase 1 / Phase 2 | terminated | May 16, 2017 | BioLineRx, Ltd. | Due to lack of enrollment | Enrollment / accrual |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801),… | Phase 1 | terminated | May 21, 2018 | Pfizer | A business decision was made by Pfizer to terminate the study. Termination was not due to any… | Safety / toxicity |
| NCT03603964 | Guadecitabine Extension Study | Phase 2 | terminated | Jul 27, 2018 | Astex Pharmaceuticals, Inc. | Early termination not due to patient safety | Safety / toxicity |
| NCT05569512 | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation… | Phase 1 | terminated | Oct 6, 2022 | Malika Kapadia | On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for… | Investigator |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With… | Phase 1 | withdrawn | Aug 23, 2023 | Medical College of Wisconsin | Sponsor withdrew support. | Other (stated, no rule matched) |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | Phase 1 | terminated | Feb 2, 2015 | Menarini Group | The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of… | Safety / toxicity |
| NCT05028751 | A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants… | Phase 1 / Phase 2 | terminated | Aug 31, 2021 | Kronos Bio | Sponsor decision | Sponsor / business decision |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive…(Pediatric AML) | Phase 1 | withdrawn | Nov 18, 2022 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Phase 1 / Phase 2 | terminated | Aug 30, 2007 | Astex Pharmaceuticals, Inc. | Recommended Phase II dose determined | Other (stated, no rule matched) |
| NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With… | Phase 1 | terminated | Nov 7, 2019 | Astex Pharmaceuticals, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)… | Phase 1 | terminated | Nov 19, 2020 | Astex Pharmaceuticals, Inc. | termination due to portfolio prioritization | Sponsor / business decision |
| NCT03318016 | Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid… | Phase 1 | terminated | Oct 23, 2017 | University of Colorado, Denver | Low enrollment, University Scientific Review Committee required study closure. | Enrollment / accrual |
| NCT04955938 | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative… | Phase 1 | withdrawn | Jul 9, 2021 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With… | Phase 3 | terminated | Aug 6, 2018 | GlycoMimetics Incorporated | Trial failed to meet primary endpoint. | Other (stated, no rule matched) |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | Phase 1 | terminated | Jun 26, 2017 | Roncarolo, Maria Grazia, MD | Lack of Enrollment | Enrollment / accrual |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | Phase 2 | terminated | Mar 23, 2017 | Loyola University | Poor accrual | Enrollment / accrual |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic… | Phase 2 | withdrawn | Mar 29, 2024 | Northside Hospital, Inc. | Unable to accommodate FDA recommendations for protocol revisions | Other (stated, no rule matched) |
| NCT04172844 | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients…(PAVE) | Phase 1 | terminated | Nov 21, 2019 | Medical College of Wisconsin | Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no… | Other (stated, no rule matched) |
| NCT04526288 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade… | Phase 2 | terminated | Aug 25, 2020 | Fred Hutchinson Cancer Center | Terminated due to low accrual | Enrollment / accrual |
| NCT05309018 | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With…(LAMIPA) | — | withdrawn | Apr 4, 2022 | Centre Hospitalier Régional Metz-Thionville | investigator's unavailability | Investigator |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and… | Phase 1 | terminated | Jun 30, 2006 | Kyowa Kirin, Inc. | Terminated due to suboptimal dosing schedule | Other (stated, no rule matched) |
| NCT02942758 | Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With…(AML-ViVA) | Phase 2 | terminated | Oct 24, 2016 | University Hospital Regensburg | Due to financial reasons. | Funding |
| NCT02718300 | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | Phase 2 | terminated | Mar 24, 2016 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 16, 2025source: clinicaltrials